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Abstract 
Background 
Antidepressant prescribing continues to rise. Increased long-term prescribing and higher 
doses are contributing to current growth; however, patient factors associated with the use of 
higher doses remain unknown. This study?s aim was to investigate patient factors associated 
with selective serotonin re-uptake inhibitor (SSRI) prescribed daily dose for depression 
treatment in general practice. 
Methods 
A stratified sample of low to high prescribing practices were selected. Routine individual 
patient-level data were extracted one practice at a time: September 2009 to January 2011. 
Patients included were ≥18 years, and prescribed an SSRI for depression. Logistic regression 
analysis was undertaken to assess individual predictor variables on SSRI daily dose by 
standard therapeutic dose versus higher dose, as SSRIs demonstrate flat dose response curves 
for depression treatment. Predictor variables included: age, gender, deprivation, co-morbidity, 
smoking status, being prescribed the same SSRI for ≥2 years, and patients? general practice. 
For a subgroup of patients a second sub-group analysis included long-term benzodiazepine 
and/or z-hypnotic (B&Z) as a predictor variable. 
Results 
Inter-practice SSRI prescribing varied significantly; practice point prevalence ranged from 
2.5% (94/3697) to 11.9% (359/3007) of the practice population ≥18 years old; median 7.3% 
(250/3421) (χ2 = 2277.2, df = 10, p < 0.001). Overall point prevalence was 6.3% 
(3518/52575), with 5.8% (3066/52575) prescribed SSRIs for depression of whom 84.7% 
(2596/3066) had data for regression analysis. Higher SSRI doses were significantly 
associated with, in descending order of magnitude, individual practice attended, being 
prescribed the same SSRI for ≥2 years (Odds Ratio (OR) 1.80, 95% CI 1.49 to 2.17, p < 
0.001) and living in a more deprived area (OR 1.55, 95% CI 1.11 to 2.16, p = 0.009). Higher 
SSRI doses in the B&Z subgroup were significantly associated with individual practice 
attended, being prescribed a long-term B&Z (OR 2.05 95% CI 1.47 to 2.86, p < 0.001) and 
being prescribed the same SSRI for ≥2 years (OR 1.94, 95% CI 1.53 to 2.47, p < 0.001). 
Conclusion 
Higher SSRI doses for depression were associated with practice attended and being 
prescribed the same antidepressant for ≥2 years. As long-term antidepressant use increases, 
the use of higher doses may further contribute to prescribing growth. 
Keywords 
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Background 
Antidepressant prescribing has increased substantially across Europe, USA and Australia 
over the last 40 years [1-5] and has attracted much discussion, debate and concern over the 
last 40 years [1,6,7]. In Scotland it was estimated that 11.3% of the adult population were 
prescribed antidepressants in 2010/11 [8]. Concerns over the number of people receiving 
antidepressants and increased prescribing led the Scottish Government in 2007 to set Health 
improvement, Efficacy, governance, Access to services and Treatment (HEAT) targets to 
reduce prescribing. These targets were not met due to poor target design and limited 
knowledge about antidepressant prescribing and use [9]. 
As elsewhere, the majority of antidepressants are prescribed by general practitioners (GPs) 
for the treatment of depression [10-12] with the rest prescribed for other conditions [13,14]. 
Although prescribing continues to increase, there is no clear corresponding increase in 
depression incidence or prevalence [15,16]. Increased prescribing has so far been explained at 
national and local levels by a combination of factors: increased selective serotonin re-uptake 
inhibitor (SSRI) use [2,5], increased long-term prescribing [16] and the probable use of 
higher doses [12,17]. SSRIs are of particular interest as they account for 53% of all 
antidepressant prescriptions and 67% of all antidepressant defined daily doses (DDDs) 
prescribed [8]. DDDs are units of measurement defined by the World Health Organization as 
?the assumed average maintenance dose per day for a drug used for its main indication in 
adults?. DDDs do not necessarily reflect the recommended or prescribed daily dose but allow 
a convenient method to compare prescribing volumes between organisations [18]. 
There are large variations in prescribing between practices which are influenced by practice 
level characteristics: list size, number of GPs, proportion of female GPs, and population 
factors including age, gender, deprivation and long-term illness [19]. Depression prevalence 
is influenced by similar factors with chronic diseases such as diabetes, coronary heart disease, 
stroke, hypertension, asthma or chronic obstructive pulmonary disease (COPD) increasing 
individuals? depression risk [20,21]. Smoking has also been reported to have a bidirectional 
relationship with depression and may influence antidepressant response [22]. We were also 
interested in the influence of benzodiazepines and/or z-hypnotics (B&Zs) due to their 
negative effects on depression and weak associations with antidepressant prescribing [23-25]. 
The majority of published studies exploring factors relating to prescribing volumes lack 
patient-level information, such as antidepressant indication and dose [2,5,15-17,19]. 
Although antidepressant doses are one factor which may contribute to current growth and 
prescribing variations, it remains unclear to what extent individual patient factors influence 
daily dose. A better understanding of these may enable the development of strategies 
supporting more appropriate antidepressant prescribing. 
Therefore, the aim of this study was to investigate which patient-level factors independently 
associated with SSRI prescribed daily dose for the treatment of depression in general 
practice. 
Methods 
Setting and design 
This cross sectional study is a secondary analysis of routinely available data from a stratified 
sample of low to high volume antidepressant prescribing general practices in the NHS 
Greater Glasgow and Clyde (NHSGG&C). NHSGG&C provides healthcare services for a 
diverse population of approximately 1.2 million people across a varied urban area containing 
269 general practices, and in response to the HEAT target committed to further understanding 
current practice and supporting appropriate antidepressant use [26]. 
The 269 practices were ranked low to high antidepressant prescribers, by defined daily doses 
(DDDs)/1000 patients from Prescribing and Information System for Scotland (PRISMS) for 
year to March 2009. PRISMS is a web-based application providing information for all 
community dispensed prescriptions, and can be interrogated to provide practice level reports. 
Ranked practices were then categorised as low (practice 1 to 89: 8,076 to 25,657 DDDs/1000 
patients), medium (practice 90 to 179: 25,666 to 34,872 DDDs/1000 patients) and high 
(practice 180 to 269: 34,886 to 65,409 DDDs/1000 patients) prescribers; practices were 
recruited from each category with varying characteristics known to influence antidepressant 
volumes: practice size and deprivation code [19]. Other factors such as patient ethnicity, GP 
training and country of birth, and practice rurality although known to influence antidepressant 
volumes [19] were not included due to unreliable data quality and NHSGG&C serving an 
urban area. 
Practices within each prescribing category with a mixture of characteristics were invited to 
participate in HEAT target service evaluation work through a third party; their local 
Community Health and Care Partnership (CHCP) prescribing support team. In 2009 
NHSGG&C consisted of 10 CHCPs serving populations with varying levels of deprivation. 
CHCP prescribing support teams serving areas of low to high deprivation were asked to 
select and approach potential practices for participation in HEAT target service evaluation 
work. Six CHCPs supported practice recruitment with 12 practices agreeing to participate. 
Ethical opinion was sought from the West of Scotland Research Ethics Service on the use of 
anonymised patient-level data for this study; however, the ethics service considered this study 
to be service evaluation not requiring ethics service approval, although Caldicott Gaurdian 
approval would be required [27]. Eleven of the 12 practices gave Caldicott Guardian approval 
to use anonymised patient-level data (Table 1); one medium prescribing practice declined 
approval to use anonymised data and were excluded. All practices were ?paper-light?, 
recording clinical information electronically for >5 years on individual practices? General 
Practice Administration System Scotland (GPASS). GPASS was the most widely used 
general practice system in NHSGG&C at this time. 
Table 1 Practice characteristics 
Practice *ADM volume 
DDDs/1000 patients 
(Category) 
SSRI volume 
DDDs/1000 
patients (%)? 
Total practice 
population ≥18 years 
(female:male) 
Number 
of GPs 
?SIMD 
quintile 
Training 
practice 
% patient prescribed an SSRI 
(number of patients/practice 
population ≥18 years) 
1 9,576 (L) 6,933 (72.4) 3697 (1072:2625) 2 4 No 2.5% (94/3697) 
2 18,295 (L) 12,630 (69.0) 9806 (5327:4479) 5 5 Yes 3.4% (337/9806) 
3 20,752 (L) 14,600 (70.4) 6736 (3601:3135) 6 1 Yes 5.2% (353/6736) 
4 28,169 (M) 19,714 (70.0) 4324 (2262:2062) 5 4 Yes 6.0% (261/4324) 
5 29,894 (M) 20,860 (69.8) 5741 (2964:2777) 4 5 No 8.5% (487/5741) 
6 31,038 (M) 20,967 (67.6) 3421 (1657:1764) 3 4 No 7.3% (250/3421) 
7 35,490 (H) 25,448 (71.7) 3956 (2005:1951) 3 2 No 7.6% (299/3956) 
8 41,917 (H) 26,710 (63.7) 5010 (2493:2517) 6 5 Yes 9.0% (451/5010) 
9 44,637 (H) 30,344 (68.0) 3121 (1653:1468) 3 5 No 8.4% (262/3121) 
10 49,393 (H) 31,885 (64.6) 3756 (1888:1868) 4 4 Yes 9.7% (365/3756) 
11 65,409 (H) 46,309 (70.8) 3007 (1550:1457) 2 5 Yes 11.9% (359/3007) 
*From Prescribing Information Systems Scotland (PRISMS) data year to March 2009. 
ADM: antidepressant medicines. DDDs: defined daily doses. 
Category: Ranked as L ? Low, M ? Medium and H ? Hig h prescribers from PRISMS. 
SSRI: selective serotonin re-uptake inhibitors. ? % of total antidepressant DDDs/1000 patients. 
SIMD: Scottish Index of Multiple Deprivation, ?categorise by practice postcode quintile 1 (least deprived) to 5 (most deprived). 
The patient demographics represented by the 11 study practices are similar to 47% 
(481/1014) of Scottish general practices by urban setting, proportion of patients aged 15 to 74 
years old and patient-level SIMD deprivation quintiles. These 481 practices serve 55% (3/5.5 
million people) of the Scottish population with 202 of these practices being in NHSGG&C 
serving 1 million people [28]. 
Identification of study participants 
A single cross sectional data extraction was made for each practice between September 2009 
and January 2011. A prescribing support pharmacist used electronic data extraction tools 
specifically designed and piloted to identify all patients prescribed an SSRI within the 
previous 3 months, and whether the same patients were prescribed the same SSRI for ≥2 
years from individual practices? GPASS. As current guidelines recommend up to 2 years 
antidepressant treatment for those at higher risk of relapse [29-31], this was considered an 
appropriate measure of long-term antidepressant use. Patients were included if they were ≥18 
years old and prescribed an SSRI to treat depression, including mixed depression anxiety. 
The tools simultaneously gathered individuals? antidepressant prescription information, age, 
gender, co-morbidities (Read Codes for diabetes, coronary heart disease, stroke, 
hypertension, asthma or COPD), smoking status and Scottish Index of Multiple Deprivation 
(SIMD) code derived from each patient?s residential postcode [32]. Co-morbidities and 
smoking status information was readily available, having been recorded and monitored as 
part of the general practice General Medical Services contract; Quality Outcomes 
Framework; details of Read Codes are provided in Appendix 1. 
We were aware of limitations with using depression Read Codes as a marker of 
antidepressant indication as there is no contractual obligation for GPs to code patients 
receiving treatment for depression. Read Codes are a standard hierarchical classification 
system for recording patient medical information in UK primary care [33]. Previous studies 
highlighted a lack of documented diagnosis [10,34], and audits in five NHSGG&C practices 
demonstrated <50% of patients receiving antidepressant treatment for depression were coded 
for depression. Therefore the primary indication was identified using a combination of 
electronic GPASS Read Codes and patient encounter information. For a small minority of 
patients electronic records of antidepressant indications were not available from GPASS 
therefore individuals? clinical notes were manually checked for antidepressant indication at 
the date of initiation by NHS staff before the data set was anonymised. Patients with no clear 
indication were recorded as indication unknown and excluded. 
For a subset of 7 practices benzodiazepine and/or z-hypnotic (B&Z) long-term prescribing 
data were simultaneously collected, as previous practice level studies indicate an association 
between antidepressant and B&Z prescriptions [25,35]. However, data was not collected from 
4 practices due to limited staff and time resources. The 7 practices were comparable by by 
urban setting, proportion of patients aged 15 to 74 years old and patient-level SIMD 
deprivation quintiles to 251 Scottish practices serving 1.5 million people, 124 of these 
practices being within NHSGG&C. Long-term use was defined as ≥8 weeks continuous use 
as the majority of B&Zs are licensed for short-term use of 2-4 weeks [13]. 
Data operationalisation and statistical analysis 
Explanatory variables were included in a statistical model which we hypothised from the 
literature would influence SSRI prescribed daily dose, and are known to be associated with 
depression and variations in general practice antidepressant prescribing [19-22,25,35]. These 
were individuals? age, gender, residential SIMD quintile, co-morbidity status, smoking status, 
being prescribed the same SSRI for ≥2 years, and their GP practice. Co-morbidity was 
categorised into three options, having none, one or ≥2 co-morbidities. 
The outcome variable of interest was patients? SSRI prescribed daily dose, expressed as 
DDDs, as defined by WHO [18]. For example, a prescribed daily dose of 20 mg or 30 mg 
citalopram was recorded as 1 DDD or 1.5 DDDs, respectively. The statistical distribution of 
SSRI DDD data was decidedly ?non-normal?, and was ?tooth-like? with substantial bimodal 
peaks observed at DDD equivalents of 1.0 and 2.0. As SSRIs demonstrate a flat dose 
response curve for the treatment of depression with 1 DDD representing a therapeutic dose 
[18,29-31,36,37], the outcome variable of prescribed daily dose was dichotomised as a binary 
outcome variable of ≤1 or >1 DDD i.e. those with a standard therapeutic dose versus those 
with a higher dose. Knowing that a DDD equal to 2 was not necessarily twice as effective as 
a DDD equal to 1, it was decided to adopt a logistic regression model in preference to an 
ordinal logistic model. 
A multi-level model (MLM) was considered to take account of clustering within practices, 
however practice level variables were crude and the number of practices were relatively low 
limiting the meaningful use of the feature of clustering within practices in a statistical model. 
Very little work has been published to date on the minimum number of clusters required for 
an MLM, however an exploratory analysis done elsewhere suggested there should be at least 
10 to 15 clusters [38], therefore with 11 practices the dataset was on the margins of what may 
be robust approach. As the practices were not selected at random and rather were a stratified 
selection, fitting practice as random effects variable was ruled out. It was hypothesised that 
the individual patient-level factors would be more explanatory of the variability in SSRI 
prescribing than of practice level factors, and that we could retain practice attended as a fixed 
effect patient-level variable in a pooled practice model, provided the heterogeneity of the 
coefficients of each explanatory variable was not dramatically different. To test this we ran a 
logistic regression model for each practice in turn and tabulated variable coefficients with any 
statistical significance for gender, age, co-morbidities, smoking status, SIMD code derived 
from patients? residential postcode and the use of the same SSRI for ≥2 years. We found that 
practices did not dramatically differ and proceeded to use the statistical model with practice 
attended as a patient-level fixed effect variable using the pooled patient data from all 
practices. 
Exploratory analysis revealed a curvilinear relationship with age and prescribed daily dose. 
Different transformations for age were undertaken and although they improved model fit, the 
model failed to meet statistical assumptions. However by truncating at ≤70 years, these 
assumptions were met and this upper age limit was retained in the model. 
The approach taken was one of a full model fitting all predictor variables we hypothesised 
from existing evidence which were known to have an effect on antidepressant prescribing. 
We then used backwards stepwise elimination of variables in turn of those which did not 
achieve a significance level of p = 0.05 to explore what effect was achieved in gaining model 
parsimony i.e. the best model ?fit? with the fewest number of predictor variables. We pre-
specified a low significance level of p = 0.05 as a cut-off in eliminating variables in turn as 
the dataset contained a large number of individuals enabling statistical significance to be 
more easily achieved. We retained variables greater or equal to p = 0.05 if they improved 
model fit. 
A second logistic regression analysis was also undertaken for the subgroup of patients from 7 
practices with data on long-term B&Z prescribing. B&Z data were categorised into a variable 
with two groups, being prescribed a B&Z long-term or not. 
Data were analysed using Stata 11.2. 
Results 
Inter-practice SSRI prescribing varied significantly; practice point prevalence ranged from 
2.5% (94/3697) to 11.9% (359/3007) of the practice population ≥18 years old; median 7.3% 
(250/3421) (χ2 = 2277.2, df = 10, p < 0.001). The SSRI point prevalence over all 11 practices 
was 6.3% (3518/52575) of which 67.3% (2369/3518) were female; 5.8% (3066/52575) of the 
total practice population received an SSRI for treatment of depression (Table 2). 
Table 2 Antidepressant indication 
 Number of patients prescribed an SSRI n = 3518 (%) 
Depression/Mixed depression anxiety 3066 (87.2) 
Anxiety disorder 305 (8.7) 
Bipolar 46 (1.3) 
Schizoaffective 38 (1.1) 
Personality disorder 10 (0.3) 
Unknown 18 (0.5) 
Other mental health 15 (0.4) 
Other general medical 20 (0.6) 
Other mental health: insomnia, eating disorders, etc. 
Other general medical: neuropathy, menopausal symptoms, irritable bowel syndrome, 
premature ejaculation, etc. 
Significantly higher SSRI doses were prescribed to ≤70 years old than those >70 years (mean 
? SD), 1.43 ? 0.69 DDDs versus 1.12 ? 0.51 DDDs (Ma nn-Whitney U test p < 0.001). There 
was no significant difference in SSRI prescribed daily dose by gender within the age groups. 
Regression analysis 
97.5% (2596/2662) of those ≤70 years had complete data for all predictor variables, and were 
entered into a logistic regression model (Table 3). We hypothesised an age gender interaction 
term would be necessary as women live longer than their male counterparts and older age is 
associated with lower SSRI doses; however, the interaction term was not significant, did not 
improve model fit, and was left out. All the model assumptions held: there was no evidence 
of multi-collinearity (no variables were highly correlated >0.8), the link test was correctly 
specified (hatsq z = 0.90; p = 0.37), and Hosmer and Lemeshow?s goodness of fit test failed 
to achieve significance (Chi-square (8) = 6.10; p = 0.64). No outliers were excluded for 
having disproportionate leverage on the model. 
Table 3 Patient demographics and independent variables 
 n = 2662 Unadjusted Odds Ratio (95% CI) p-value 
Mean Age ? SD (range) years 45 ? 13 (18 to 70) 1.00  (0 .99 to 1.01) 0.85 
Male (%) 884 (33.2) 1  
Female (%) 1778 (66.8) 1.03 (0.86 to 1.23) 0.734 
Deprivation (%) 
SIMD quintile 1(least deprived) 248 (9.3) 1  
SIMD quintile 2 322 (12.1) 1.17 (0.80 to 1.72) 0.41 
SIMD quintile 3 167 (6.3) 1.67 (1.08 to 2.58) 0.021 
SIMD quintile 4 522 (19.6) 1.38 (0.98 to 1.94) 0.068 
SIMD quintile 5 (most deprived) 1364 (51.2) 1.55 (1.11 to 2.16) 0.009 
SIMD unknown (not in model) 39 (1.5)   
?Co-morbidities (%) 
0 1728 (64.9) 1  
1 665 (25.0) 1.10 (0.90 to 1.33) 0.356 
≥2 269 (10.1) 1.18 (0.90 to 1.54) 0.238 
Current Smoking Status (%) 
Non-smoker 1581 (59.4) 1  
Smoker 1050 (39.4) 1.13 (0.95 to 1.34) 0.165 
Smoking status unknown (not in model) 31 (1.2)   
SSRI use (%) 
ADM for <2y (%) 1909 (71.7) 1  
Same ADM for ≥2y 753 (28.3) 1.80 (1.49 to 2.17) <0.001 
Practice (% practice pop.) 
1 82 (2.2) 1  
2 265 (2.7) 1.98 (1.09 to 3.57) 0.024 
3 242 (3.6) 1.26 (0.68 to 2.35) 0.461 
4 191 (4.4) 3.26 (1.77 to 5.99) <0.001 
5 372 (6.5) 1.50 (0.84 to 2.69) 0.171 
6 201 (5.9) 2.69 (1.47 to 4.94) 0.001 
7 224 (5.7) 2.20 (1.21 to 4.01) 0.01 
8 322 (6.4) 1.81 (1.01 to 3.24) 0.047 
9 181 (5.8) 3.80 (2.06 to 7.01) <0.001 
10 302 (8.0) 2.32 (1.29 to 4.18) 0.005 
11 280 (9.3) 3.54 (1.96 to 6.38) <0.001 
Odds ratio: unadjusted. CI: 95% confidence interval. SD: standard deviation. SIMD: Scottish 
Index of Multiple Deprivation. SSRI: selective serotonin re-uptake inhibitor. ADM: 
antidepressant medicine. 
?Co-morbidities: Individuals had one or more of the following: asthma, COPD, 
cardiovascular disease, stroke, diabetes mellitus and/or hypertension. 
Higher prescribed daily dose was significantly associated with the following variables in 
descending order of magnitude by odds ratios: individual practice attended, being prescribed 
the same SSRI for ≥2 years, and living in a more deprived area (Table 3). There were 
significant differences between doses for those prescribed SSRIs short-term versus those 
prescribed the same SSRI for ≥2 years (Table 4), with significant increases observed for all 
SSRIs except paroxetine and escitalopram. 
Table 4 Mean daily doses and differences in short-term and long-term (same SSRI ≥2 years) mean doses 
 ADM <2 years (n = 1909) ADM ≥2 years (n = 753) Difference in mean dose 
(mg) 95% CI 
Mann-Whitney 
U-test? 
All ADMs (n = 2662) 
Number of 
ADMs (%)? 
Mean dose 
(SD) mg 
Number of 
ADMs (%)? 
Mean dose 
(SD) mg 
Number of 
ADMs (%) 
Mean dose 
(SD) mg 
Citalopram 929 (34.9%) 25.8 (12.2) 258 (9.7) 31.2 (14.8) 5.4 (3.6 to 7.2) <0.001 1187 (44.6) 27.0 (13.0) 
Fluoxetine 753 (28.3) 27.2 (12.0) 316 (11.9) 30.6 (14.0) 3.4 (1.6 to 5.2) <0.001 1069 (40.2) 28.2 (12.7) 
Sertraline 147 (5.5) 91.0 (43.7) 76 (2.9) 106.6 (49.2) 15.6 (2.3 to 28.8) 0.019 223 (8.4) 96.3 (46.1) 
Paroxetine 35 (1.3) 28.0 (11.8) 67 (2.5) 29.4 (12.7) 1.4 (-3.6 to 6.4) 0.832 102 (3.8) 28.9 (12.3) 
Escitalopram 44 (1.7) 15.2 (5.6) 35 (1.3) 15.4 (6.8) 0.2 (-2.6 to 3.0) 0.94 79 (3.0) 15.3 (6.1) 
Fluvoxamine 1 (0.0)  1 (0.0)    2 (0.1)  
Total 1909 (71.7)?  753 (28.3)?    2662 (100%)  
Note: Total mean dose and difference in doses between short-term and long-term use presented as means and SD to aid clarity of actual 
differences groups. 
ADMs: antidepressant medicines. SD: standard deviation. 
?: Percentage of total antidepressants prescribed to the 2662 patients. 
?: Dose distribution for ADM <2 years and ≥2 years compared using Mann-Whitney U-test. 
Long-term B&Z use 
Seven practices had data available for a subsequent analysis exploring B&Z association with 
SSRI prescribed daily dose. 11.8% (190/1610) of the subset were prescribed long-term 
B&Zs; 1567 (97.3%) had complete data and were included. In this analysis, we found higher 
prescribed daily dose was significantly associated with the following variables in descending 
order of magnitude by odds ratios: individual practice attended, being prescribed long-term 
B&Z and being prescribed the same SSRI for ≥2 years (Table 5). All the model assumptions 
held: there was no evidence of multi-collinearity (no variables were highly correlated >0.8), 
the link test was correctly specified (hatsq z = 0.87; p = 0.39) and Hosmer and Lemeshow?s 
goodness of fit test failed to achieve significance (Chi-square (10) =3.24; p = 0.92). 
Table 5 Patient demographics and independent variables, including benzodiazepines 
and z-hypnotics 
 n = 1610 Unadjusted Odds Ratio (95% CI) p-value 
Mean Age ? SD (range) years 46 ? 12 (18 to 70) 1.00  (1.00 to 1.01) 0.432 
Male (%) 551 (34.2) 1  
Female (%) 1059 (65.8) 1.17 (0.93 to 1.46) 0.186 
Deprivation (%) 
SIMD quintile 1(least deprived) 93 (5.9) 1  
SIMD quintile 2 153 (9.7) 0.92 (0.50 to 1.70) 0.794 
SIMD quintile 3 90 (5.7) 1.75 (0.90 to 3.43) 0.101 
SIMD quintile 4 264 (16.7) 1.29 (0.73 to 2.28) 0.373 
SIMD quintile 5 (most deprived) 985 (62.1) 1.41 (0.82 to 2.44) 0.213 
SIMD unknown (not in mode) 25 (1.6)   
?Co-morbidities (%) 
0 1028 (63.9) 1  
1 415 (25.8) 1.20 (0.93 to 1.55) 0.152 
≥2 167 (10.4) 1.12 (0.79 to 1.58) 0.533 
Current Smoking Status (%) 
Non-smoker 900 (56.6) 1  
Smoker 691 (43.4) 1.16 (0.93 to 1.45) 0.192 
Smoking status unknown (not in model) 19 (1.2)   
SSRI use (%) 
ADM for <2y (%) 1143 (71.0) 1  
Same ADM for ≥2y 467 (29.0) 1.94 (1.53 to 2.47) <0.001 
Practice (% practice pop.) 
1 82 (5.1) 1  
3 242 (15.0) 1.48 (0.77 to 2.83) 0.241 
6 201 (12.5) 2.78 (1.49 to 5.18) 0.001 
8 322 (20.0) 1.96 (1.07 to 3.58) 0.029 
9 181 (11.2) 4.17 (2.22 to 7.81) <0.001 
10 302 (18.8) 2.60 (1.42 to 4.78) 0.002 
11 280 (17.4) 3.62 (1.98 to 6.66) <0.001 
B&Z use (%) 
None 1420 (88.2) 1  
Long-term B&Z for ≥8 weeks 190 (11.8) 2.05 (1.47 to 2.86) <0.001 
CI: 95% confidence interval. SD: standard deviation. SIMD: Scottish Index of Multiple Deprivation. 
SSRI: selective serotonin re-uptake inhibitor. ADM: antidepressant medicine. 
?Co-morbidities: Individuals had one or more of the following: asthma, COPD, cardiovascular 
disease, stroke, diabetes mellitus and/or hypertension. 
B&Z: benzodiazepine and/or z ?hypnotic. 
Discussion 
Summary of main findings 
Higher SSRI doses for depression treatment were statistically significantly associated with 
the following variables in descending order of magnitude by odds ratios: individual practice 
attended, being prescribed the same SSRI for ≥2 years and living in a more deprived area. 
When long-term B&Z prescribing was explored as an explanatory variable in a separate 
analysis, SSRI doses were found to statistically significantly associated with: individual 
practice attended, long-term B&Z prescribing and being prescribed the same SSRI for ≥2 
years. 
Strengths and limitations 
The use of patient-level data, specifically individuals? antidepressant dose and indication, 
enabled this study to overcome limitations of previous studies [2,15-17,19,39]. By excluding 
non-mental health and non-depression SSRI use we identified characteristics associated with 
individuals receiving higher SSRI doses for the treatment of depression only. 
Unlike other antidepressants, SSRIs demonstrate a flat dose response curve for the treatment 
of depression with higher than standard doses (>1 DDD) being of questionable benefit [29-
31,36,37]. Therefore the use of logistic regression enabled the identification of patient-level 
variables associated with differences in SSRI standard therapeutic doses versus those on 
higher doses which are of clinical interest and possibly of more importance in the long-term 
use of SSRIs. 
However this study has some limitations. The cross sectional nature of the study does not 
permit any analysis of dose progression in time from first starting an antidepressant; dose 
values captured may be discontinued, reduced or increased soon after data capture. As data 
capture was staggered from September 2009 to January 2011 the release of updated and new 
guidance may have influenced prescribing, although the guidance did not advise new changes 
in antidepressant doses they further highlighted the non-pharmacological management of 
depression [30,40,41], but antidepressant growth has steadily and consistently continued on 
average to increase by 5% per annum since 2004/05 with no clear change in trajectory since 
the introduction of updated and new guidance [8]. However we cannot rule out that practices 
at the end of the data collection period may have changed practice in response to the updated 
and new guidance. 
Another possible confounding factor which may have influenced our results were not 
knowing whether patients took their medicines as prescribed, however only those for whom 
prescriptions for the SSRIs were issued within the three months prior to data capture were 
included, and we knew that patients prescribed the same SSRI for ≥2 years were issued with 
regular SSRI prescriptions. Depression severity and specialist mental health review may also 
have influenced the use higher SSRI dose, however the majority of patients with depression 
are diagnosed and treated by their GP without seeing psychiatrists or attending specialist 
mental health services, and are seen as having milder depressive symptoms [42]. Patient 
ethnicity is known to be associated with lower practice level antidepressant and B&Z 
prescribing [43,44] and inclusion in our analysis would have provided further context to this 
study; however, patient-level ethnicity data were unreliably and inconsistent which precluded 
their inclusion in this study. 
As this was not a prospective research study, and was completed as part of NHSGG&C 
service evaluation and ongoing commitment to understanding and evaluating current practice 
[26], findings may not be generalisable to other areas. However this study?s findings may be 
of interest to others working in similar urban practices with similar demographics to this 
population. 
Comparison with existing literature 
We found that 6.3% of the adult practice population were prescribed an SSRI; as expected 
this was lower than previous UK studies which focused exclusively on SSRI and non-SSRI 
prescribing: 6.9% [10], 8.6% [12] and NHS Scotland?s estimate of 11.3% [8]. The proportion 
of females and males prescribed SSRIs of 67.3% and 32.7% respectively is consistent with 
other studies [8,39], and 87.2% being prescribed an SSRI for depression is slightly higher 
than 85.4% previously reported in a general practice study including all antidepressants[45]. 
In comparison 28.3% being prescribed the same antidepressant long-term is lower than 
previous studies, 47.1% using the same definition of long-term use [12], and 40.6 to 51.4% 
[16] and 33 to 55% [10] using slightly different definitions. Differences may also reflect GPs? 
interest in depression management and optimal care, in managing depression as a long-term 
condition, and possibly not reducing review frequency as patients continue on longer 
antidepressant courses [45]. 
Previous studies indicate that individual patient-level socioeconomic deprivation is 
significantly associated with early antidepressant discontinuation [39] whereas this study 
identifies higher deprivation as having a small but significant association with higher 
prescribed daily doses. 
Complex subjective patient and prescriber factors may influence the size of prescribed daily 
doses. As patients become ?experts? in their condition they become more informed and 
enabled, making more informed decisions about medicines; possibly voicing their 
expectations and preferences to use higher antidepressant doses [46,47]. Although, 
prescribers may respond to illness severity, and perceived safety and better tolerability of 
SSRIs [48,49], as well as ?pushing the dose? as GPs have also previously been criticised for 
prescribing subtherapeutic doses of antidepressants for the treatment of depression [11]. 
However, an inextricable combination of these known, and other unknown, factors may have 
contributed to the average SSRI doses for individual drugs in this study being up to 25% 
higher for <2 years use, and up to 42% higher for those prescribed the same SSRI for ≥2 
years, when compared to previous cross sectional studies [11,50,51], and although we 
acknowledge the dose trajectory limitations of this study the routine use of such higher doses 
will further drive total antidepressant prescription and DDD volumes as SSRI account for the 
majority of antidepressants prescribed in Scotland [8]. 
Unexpectedly, in contrast to practice level studies, prescribed daily dose was not associated 
with co-morbidity [19]. This suggests that high disease burden practices are treating more 
patients with antidepressants rather than prescribing higher doses to fewer patients. This 
study did not find any association between SSRI dose and smoking which is suspected to 
influence antidepressant response [22]. However, long-term B&Z use was associated with 
higher SSRI doses which is compatible with previous observations of increased long-term 
(>4 weeks) B&Z use with SSRIs [35]. 
Implications for practice and research 
The overarching challenge for current and future practice is continuing support and 
management for people with common mental health problems, such as depression which is 
relapsing and remitting, and of a long-term nature. Pragmatically, as long-term prescribing 
increases [16] and frequency of review decreases with antidepressant duration [45], more 
consideration should be given to managing depression as a long-term condition. This would 
enable opportunities to review and optimise care to match individuals? needs whether that be 
pharmacological, non-pharmacological, non-medicalised or a combination of these [12,52]. 
In line with current guidance [29-31,40] standard medical texts such as the British National 
Formulary should consider including information highlighting differences in antidepressant 
dose response effects for the treatment of depression as, unlike tricyclic antidepressants 
(TCAs), SSRIs have traditionally been prescribed at therapeutic doses [11]. Over the years 
campaigns [53] and guidelines [29-31] have advised prescribers to increase antidepressant 
doses to achieve better drug response and remission of depressive symptoms. However this 
advice is appropriate for routine use of TCAs and venlafaxine but not SSRIs, due to their flat 
dose response curve [29-31,40]; higher doses do not routinely provide better efficacy [29-31] 
but increase the risk of adverse effects such as anxiety and/or insomnia [36,54]. Such adverse 
effects may influence combination antidepressant use and/or concomitant B&Z use [35,55] 
with regular B&Z use negatively affecting depression and/or anxiety symptoms [23,24] 
possibly resulting in SSRI doses being ?pushed? further. As 1 in 10 patients in the B&Z 
subgroup analysis were prescribed long-term B&Zs and an SSRI, and considering B&Zs 
negative effects, patients prescribed such combinations should be considered a priority for 
ongoing review and follow up to minimise inappropriate prescribing, and reduce and stop 
B&Z use where possible. 
The difference in short-term and long-term doses raises complex questions such as whether 
patients are receiving the most effective drug and dose in line with guidance [29,30]; what is 
the potential loss of antidepressant efficacy with treatment duration [56,57] where some 
patients respond to ?pushing the dose? and others dose reduction [56]; whether 
neuroprogressive changes in depression affect drug response [58], and the challenge of 
accurately diagnosing depression [34,59-61]. 
Future research should consider prospective longitudinal studies assessing antidepressant 
response and outcomes, dose response and changes over treatment lifetime. Qualitative 
approaches have a role in exploring service user expectations of antidepressant treatment and 
dose; why GPs ?push the dose? and how continuing care is provided. A comprehensive study 
specifically designed as a research study with data collected from sufficient randomly 
sampled GP practices to permit a multi-level model including patient-level and GP practice-
level variables is warranted to contextualise these patient-level factor findings. 
Conclusion 
This study has demonstrated that higher SSRI prescribed daily doses for depression are 
associated with patients? GP practice attended and being prescribed the same antidepressant 
for ≥2 years. As long-term antidepressant use increases, the use of higher doses may further 
contribute to prescribing growth. However, the routine use of such higher SSRI doses for 
depression is not supported by current evidence or guidelines. Therefore, in the short-term, 
lower prescribing could be achieved via audit and feedback of practice prescribing patterns 
[62] and GP face-to-face reviews of those already on long-term antidepressants [12] which 
have both been effective in reducing costs and prescribing volumes. 
Appendix 1 Data extraction information and Read Codes 
Condition Code Clinical concept Contract code? 
Depression E112. Single major depressive episode 
 
 
E113. Recurrent major depressive episode 
 
 
E118. Seasonal affective disorder 
 
 
E11y2 Atypical depressive disorder 
 
 
E11z2 Masked depression 
 
 
E135. Agitated depression 
 
 
E2003 Anxiety with depression yes 
 
E291. Prolonged depressive reaction 
 
 
E2B.. Depressive disorder NEC 
 
 
E2B1 Chronic depression 
 
 
Eu204 [X]Post-schizophrenic depression 
 
 
Eu32. [X]Depressive episode yes 
 
Eu33. [X]Recurrent depressive disorder yes 
 
Eu341 [X]Dysthymia 
 
 
Eu412 [X]Mixed anxiety and depressive disorder 
 
 
Encounters depression, depressive, depre* 
 
Other co-morbidities 
Asthma H33.. Asthma 
 
 
H33zz Asthma NOS yes 
 
21262 Exlcude if asthma resolved 
 
COPD H3?  Chronic obstructive pulmonary disease 
 
 
H3y.. Other specified chronic obstructive airways disease 
 
 
H3z.. Chronic obstructive airways disease NOS yes 
 
H31.. Chronic bronchitis 
 
 
H32.. Emphysema 
 
 
H36.. Mild chronic obstructive pulmonary disease 
 
 
H37.. Moderate chronic obstructive pulmonary disease 
 
CVD G3?  Ischaemic heart disease 
 
 
G3z.. Ischaemic heart disease NOS yes 
 
G30.. Acute myocardial infarction 
 
 
G30z. Acute myocardial infarction yes 
Stroke G6?  Cerebrovascular disease 
 
 
G64z. Cerebral infarction NOS yes 
Hypertension G2?  Hypertensive disease yes 
 
G20.. Essential hypertension 
 
Diabetes C10.. Diabetes mellitus 
 
 
C10E. Type 1 diabetes mellitus yes 
 
C10F. Type 2 diabetes mellitus yes 
Bipolar illness E11.. Manic-depressive psychoses 
 
 
Eu31. [X]Bipolar affective disorder yes 
Schizophrenia E10.. Schizophrenia 
 
 
E10z. Schizophrenia NOS yes 
 
Encounters Schizophren* 
 
OCD E203. Obsessive compulsive disorder 
 
 
Encounters Compul* 
 
Anxiety E200. Anxiety states 
 
 
Eu431 [X]Post - traumatic stress disorder 
 
 
E29y1 Post-traumatic stress disorder 
 
 
E2001 Panic disorder 
 
 
E2022 Panic disorder 
 
 
E202. Phobic states 
 
 
Encounters phob* 
 
Eating disorders E271. Anorexia nervosa 
 
 
E2751 Bulimia nervosa 
 
Smoking 137R. Current smoker yes 
 
137S. Ex smoker yes 
 
137 L. Current non-smoker yes 
?Defined by Scottish Clinical Information Management in Practice January 2009 (Ref M). All 
practices used NHSGG&C long-term condition templates for contract work and data 
recoding consistency. 
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